CEO Executive AssistantA global commercial launch is the most compressed, highest-stakes period in a pharmaceutical CEO’s calendar. Every function in the company is operating at full intensity simultaneously: commercial operations finalizing launch sequencing across markets, medical affairs building out the field team, market access teams in final payer negotiations, and investor relations fielding questions about peak sales estimates. And underneath all of it, the pipeline does not pause.
CEOs who manage this period well share one trait: they have decided in advance which decisions only they can make, and they have offloaded everything else before the launch window opens.
Why Launch Periods Destroy Executive Time
The gravitational pull of a major launch is unlike anything else in pharma. Every team leader believes their function is the one standing between success and failure. In most cases, they are partially right. The result is that every function competes for CEO bandwidth during the same 90-day window.
Without a deliberate time architecture, a pharma CEO in launch mode can easily spend 70 percent of the day responding to escalations, approvals, and update requests that should never have reached the C-suite. The strategic work, including the R&D oversight that determines the next launch, gets squeezed into leftover time.
The fix is not working harder. The fix is designing a decision filter before the launch begins.
Defining the CEO’s Launch Role in Advance
Before a launch opens, clarify three categories of involvement:
Decisions only the CEO can make. These include cross-functional trade-offs that involve major resource reallocation, any communication that involves the board or major investors, and escalations that require breaking from the approved launch strategy.
Decisions the CEO should review but not make. Market-specific launch sequencing adjustments, tactical medical affairs deployment, and pricing band decisions within pre-approved ranges all belong here. The right executive owns the call; the CEO gets a briefing.
Decisions the CEO should not see until the weekly summary. Operational execution items, territory-level updates, and individual market feedback belong here. If they rise to CEO level, there is a management problem, not a launch problem.
Communicating this framework explicitly to the leadership team before launch is non-negotiable. If the CEO does not define the filter, the team will default to escalating everything.
Structuring the Launch Week
During an active global launch, the CEO’s weekly cadence should be almost entirely predetermined. Improvised scheduling during launch is how critical oversight functions get dropped.
Weekly Anchors
A workable launch-period structure builds on four fixed anchors:
Monday: Cross-functional launch command. A standing 60-minute meeting with commercial, medical affairs, market access, and supply chain. Format is a simple traffic light across 10 to 15 key metrics. No narrative presentations. Red items get 5 minutes of discussion and an owner-assigned resolution path. This meeting replaces ad hoc escalation throughout the week.
Tuesday and Thursday: Investor and external stakeholder blocks. Concentrated investor and analyst calls, key customer meetings, and external partnership discussions. Grouping external commitments prevents them from fragmenting the internal execution week.
Wednesday: Strategic review block. Two to three hours of protected time covering pipeline updates, R&D progress reviews, and medium-term strategic decisions. During a launch, this block is the first one to get cannibalized. It should instead be the most protected. Missing R&D oversight for 90 days because of launch intensity is a trade-off most CEOs underestimate until the next IND filing is delayed.
Friday: Board and investor summary. A structured update that goes out before end of business, covering the week’s launch metrics and any escalations resolved. This reduces the volume of board member inquiries during the week itself.
The Role of the Executive Assistant During Launch
The CEO’s executive assistant becomes a critical launch infrastructure element. The assistant should have a standing brief on which meeting categories are fixed, which can flex, and the trigger conditions for interrupting blocked time. An executive assistant who understands the launch decision filter can intercept the majority of escalations that should not reach the CEO.
For a deeper view of how this support structure works in pharma specifically, see pharma CEO time management.
Managing Investor Relations Without Losing Internal Focus
The investor relations burden during a global launch is often underestimated. Major institutional investors expect frequent, substantive updates. The sell-side wants regular access. Healthcare-focused funds may be running their own channel checks and surfacing questions that require CEO-level responses.
The structural solution is to set a clear investor communications cadence before the launch window opens, communicate it publicly, and hold to it. Weekly updates to the buy-side should be handled by the CFO and IR team unless a material development requires CEO voice. The CEO should own quarterly earnings, key medical conference presentations, and any communication that touches pipeline valuation.
Protecting the CEO’s investor time from fragmenting into daily reactive calls is a joint responsibility of the IR team and the executive assistant. When investors know the cadence, they respect it. When there is no cadence, every investor believes their call is urgent.
R&D Pipeline Oversight During Launch
The clinical pipeline does not respect launch timelines. A data readout, an FDA query, or a competitor’s trial result can arrive in the middle of launch week and require CEO-level judgment.
The solution is not to reduce R&D oversight time; it is to make R&D oversight time non-negotiable even during peak launch intensity. The Wednesday strategic block described above serves this function. The CMO or CSO should be the primary escalation point for R&D developments, with clear criteria for what triggers an immediate CEO conversation versus what waits for Wednesday.
For a more detailed framework on managing this balance, see protecting R&D oversight time.
Clinical-Commercial Interface
One area where launch and pipeline intersect directly is the clinical-commercial interface: the post-marketing study commitments, label expansion data generation, and real-world evidence programs that will determine long-term commercial success. These programs require CEO visibility because they involve resource commitments across both R&D and commercial functions. They should have a standing agenda item in the Wednesday review.
Market Access: Where CEO Time Yields the Most Return
Market access is the function that most benefits from direct CEO involvement during launch, and the one where involvement is most selective.
National payer negotiations in major markets, particularly in Europe where health technology assessment timelines can compress launch revenue significantly, occasionally require CEO-level engagement to break a stalemate. The CEO’s role in those conversations is to signal long-term commitment to the market and organizational authority over the deal. This is different from running the negotiation, which belongs to the market access leadership team.
A useful framework from McKinsey’s analysis of pharma launch performance suggests that launch underperformance is most commonly traced to market access delays and HCP awareness gaps, not commercial execution failures. Knowing this, the CEO’s payer engagement time is high-return and should be planned, not reactive.
Supply Chain Visibility Without Micromanagement
During a global launch, supply chain reliability is a board-level risk. The CEO needs visibility without becoming the de facto supply chain manager.
The right structure is a single supply continuity metric in the Monday launch command meeting: units available versus units committed across top markets, with a flag if coverage falls below a defined threshold. If the flag triggers, the conversation about root cause and recovery plan happens in the same meeting. The CEO does not need to know why a specific shipment was delayed; the CEO needs to know whether supply will constrain revenue in the next 30 days.
Managing Key Talent During the Launch Sprint
High-performing launch team members are frequently recruited during an active launch. Competitors watch the filing milestones, know when launch resources are fully committed, and approach key people who are visible in the market.
The CEO’s role here is targeted retention visibility. Monthly one-on-one conversations with the five to eight critical launch leaders, including the commercial lead, head of market access, VP of medical affairs, and supply chain director, provide early signal on engagement and create a direct channel that makes those individuals less vulnerable to being poached.
These conversations are not performance management. They are relationship investment. They should be brief, candid, and genuinely two-directional. No agenda, no formal output, but consistent.
After the Launch Window
The post-launch period, roughly 6 to 18 months after first patient access, requires a deliberate rebalancing of the CEO’s time allocation. During active launch, commercial receives a disproportionate share of executive attention. After launch, R&D and corporate development need to return to their structural weight in the CEO’s calendar.
A formal post-launch calendar review, conducted at the 90-day mark, is a useful discipline. The CEO and executive assistant should audit the prior 90 days by category, compare it to the intended allocation, and reset the forward schedule accordingly.
Global commercial launches are the moments when pharmaceutical CEOs are most tested on their ability to execute without losing strategic orientation. The ones who do it well are not more capable across every dimension. They are more deliberate about where they show up and what they delegate.
That deliberateness is built before the launch opens, not improvised during it.
Related Reading
For further context, explore Pharma CEO Time Management for Autoimmune Disease Strategy and Biomarker-Driven Trial Management: What Pharma CEOs Must Decide and When.